tiprankstipranks
Alaunos Therapeutics (DE:WEK)
FRANKFURT:WEK
Holding DE:WEK?
Track your performance easily

Alaunos Therapeutics (WEK) Income Statement

0 Followers

Alaunos Therapeutics Income Statement

Last quarter (Q3 2023), Alaunos Therapeutics's total revenue was $―, a decrease of -100.00% from the same quarter last year. In Q3, Alaunos Therapeutics's net income was $-6.45M. See Alaunos Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 22Dec 21Dec 20Dec 19Dec 18
Total Revenue
$ -7.00K$ 2.90M$ 400.00K$ 0.00$ 0.00$ 146.00K
Cost of Revenue
--$ 0.00---
Gross Profit
$ -7.00K$ 2.90M$ 400.00K---
Operating Expense
$ 17.79M$ 38.03M$ 77.95M$ 80.36M$ 57.86M$ 54.05M
Operating Income
$ -35.35M$ -35.10M$ -77.55M$ -80.36M$ -57.86M$ -53.91M
Net Non Operating Interest Income Expense
$ -4.24M$ -3.15M$ -1.19M$ 0.00--
Other Income Expense
$ -1.22M$ -529.00K$ 13.00K$ 385.00K$ -59.94M$ 789.00K
Pretax Income
$ -35.65M$ -38.02M$ -78.75M$ -79.98M$ -117.80M$ -53.12M
Tax Provision
------
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -35.16M$ -38.02M$ -78.75M$ -79.98M$ -117.80M$ 137.25M
Basic EPS
------
Diluted EPS
------
Basic Average Shares
------
Diluted Average Shares
------
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 17.79M$ 38.03M$ 77.95M$ 80.36M$ 57.86M$ 54.05M
Net Income From Continuing And Discontinued Operation
$ -37.18M$ -37.73M$ -78.75M$ -79.98M$ -117.80M$ -53.12M
Normalized Income
$ -12.00M$ -30.03M-$ -79.98M$ -57.05M$ -53.27M
Interest Expense
---$ 0.00--
EBIT
$ -31.41M$ -34.86M$ -77.56M$ -79.98M$ -57.86M$ -53.91M
EBITDA
$ -26.92M$ -31.08M$ -74.58M$ -78.85M$ -57.23M$ -53.33M
Currency in USD

Alaunos Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis